[go: up one dir, main page]

PE20180411A1 - Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina - Google Patents

Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina

Info

Publication number
PE20180411A1
PE20180411A1 PE2017002785A PE2017002785A PE20180411A1 PE 20180411 A1 PE20180411 A1 PE 20180411A1 PE 2017002785 A PE2017002785 A PE 2017002785A PE 2017002785 A PE2017002785 A PE 2017002785A PE 20180411 A1 PE20180411 A1 PE 20180411A1
Authority
PE
Peru
Prior art keywords
emtricitabin
pharmaceutical formulations
formulations including
including tenofovir
tenofovir
Prior art date
Application number
PE2017002785A
Other languages
English (en)
Inventor
Joanna M Koziara
Scott Mccallister
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180411(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20180411A1 publication Critical patent/PE20180411A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA DE DOSIFICACION ORAL SOLIDA QUE COMPRENDE: A) ALAFENAMIDA DE TENOFOVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA EN UNA CANTIDAD DE 2.5% A 12%; Y B) EMTRICITABINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA; DONDE LA FORMA DE DOSIFICACION ES UN COMPRIMIDO QUE TIENE UN RECUBRIMIENTO DE PELICULA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE UNA INFECCION POR VIH
PE2017002785A 2015-06-30 2016-06-29 Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina PE20180411A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562187113P 2015-06-30 2015-06-30
US201662298373P 2016-02-22 2016-02-22
US201662301429P 2016-02-29 2016-02-29
US201662317286P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
PE20180411A1 true PE20180411A1 (es) 2018-03-01

Family

ID=56418608

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002785A PE20180411A1 (es) 2015-06-30 2016-06-29 Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina

Country Status (26)

Country Link
US (3) US20170000807A1 (es)
EP (6) EP3316868B1 (es)
JP (3) JP6667556B2 (es)
KR (2) KR102313668B1 (es)
CN (2) CN119606990A (es)
AU (3) AU2016287500B2 (es)
BR (1) BR112017027843A2 (es)
CA (1) CA2990210C (es)
CL (1) CL2017003320A1 (es)
CO (1) CO2017013293A2 (es)
CU (1) CU20170168A7 (es)
DO (1) DOP2017000306A (es)
EA (1) EA201792592A1 (es)
EC (1) ECSP17084331A (es)
ES (5) ES2925246T3 (es)
HK (1) HK1248547A1 (es)
IL (1) IL256364A (es)
MA (1) MA50541A (es)
MX (1) MX2017016806A (es)
PE (1) PE20180411A1 (es)
PH (1) PH12017502431A1 (es)
PL (5) PL4070788T3 (es)
PT (4) PT4070787T (es)
SI (4) SI3316868T1 (es)
SV (1) SV2017005601A (es)
WO (1) WO2017004244A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12019501848A1 (en) 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
ES2892123T3 (es) 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
EP3346995B1 (en) 2015-11-09 2019-08-28 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
NZ755597A (en) 2017-02-17 2023-06-30 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
EP3600332B1 (en) * 2017-03-20 2023-12-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Hiv post-exposure prophylaxis
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
MY208459A (en) 2018-03-23 2025-05-10 Eidos Therapeutics Inc Methods of treating ttr amyloidosis using ag10
MX2021001761A (es) * 2018-08-17 2021-04-19 Eidos Therapeutics Inc Formulaciones de ag10.
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
WO2021001508A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv in pediatric patients with rilpivirine
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) * 2019-12-31 2020-03-27 常州恒邦药业有限公司 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
WO2024211882A1 (en) * 2023-04-07 2024-10-10 Navinta, Llc Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN117338733B (zh) * 2023-10-12 2024-05-28 杭州和泽坤元药业有限公司 一种富马酸替诺福韦二吡呋酯片及其制备工艺
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法
CN119139247A (zh) * 2024-09-05 2024-12-17 安徽贝克生物制药有限公司 一种恩曲他滨丙酚替诺福韦复方片及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1301519T4 (da) 2000-07-21 2021-12-20 Gilead Sciences Inc Prodrugs af phosphonatnukleotidanaloger og fremgangsmåder til udvælgelse og fremstilling heraf
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2010091197A2 (en) 2009-02-06 2010-08-12 Gilead Sciences, Inc. Tablets for combination therapy
EA027768B1 (ru) 2011-08-16 2017-08-31 Джилид Сайэнс, Инк. Тенофовир алафенамида гемифумарат
JP6059255B2 (ja) * 2012-02-03 2017-01-11 ギリアード サイエンシス インコーポレーテッド ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法
US20160184332A1 (en) * 2013-08-14 2016-06-30 Ratiopharm Gmbh Medicament comprising a pharmaceutical combination of drugs
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
NO2717902T3 (es) * 2014-06-20 2018-06-23

Also Published As

Publication number Publication date
SI3607939T1 (sl) 2022-10-28
CN119606990A (zh) 2025-03-14
SI4070787T1 (sl) 2023-07-31
DOP2017000306A (es) 2018-01-15
CA2990210A1 (en) 2017-01-05
PT3316868T (pt) 2020-04-21
KR102121329B1 (ko) 2020-06-17
EP4070787A1 (en) 2022-10-12
EP4070788A1 (en) 2022-10-12
PT3607939T (pt) 2022-09-12
JP6978534B2 (ja) 2021-12-08
BR112017027843A2 (pt) 2018-09-04
KR20200067937A (ko) 2020-06-12
JP2020079304A (ja) 2020-05-28
AU2019210558B2 (en) 2021-04-22
PT4070788T (pt) 2023-06-06
AU2021202009B2 (en) 2023-04-13
US20170000807A1 (en) 2017-01-05
PL4233846T3 (pl) 2025-03-24
SI4070788T1 (sl) 2023-06-30
ECSP17084331A (es) 2018-01-31
ES2945345T3 (es) 2023-06-30
HK1248547A1 (zh) 2018-10-19
SI3316868T1 (sl) 2020-04-30
CN107847450A (zh) 2018-03-27
EP3316868A1 (en) 2018-05-09
MA50541A (fr) 2021-04-07
AU2021202009A1 (en) 2021-04-29
EP4233846A2 (en) 2023-08-30
EP4527467A3 (en) 2025-05-21
AU2016287500B2 (en) 2019-05-02
MX2017016806A (es) 2018-05-07
AU2019210558A1 (en) 2019-08-15
JP2021185188A (ja) 2021-12-09
EP4070788B1 (en) 2023-03-22
US20180177734A1 (en) 2018-06-28
JP6667556B2 (ja) 2020-03-18
PT4070787T (pt) 2023-05-22
EP4233846C0 (en) 2024-12-04
ES2786549T3 (es) 2020-10-13
ES3007987T3 (en) 2025-03-21
WO2017004244A1 (en) 2017-01-05
EP4070787B1 (en) 2023-03-01
JP2018519297A (ja) 2018-07-19
PL4070788T3 (pl) 2023-07-10
SV2017005601A (es) 2018-05-04
EP4527467A2 (en) 2025-03-26
PL3607939T3 (pl) 2022-11-07
AU2016287500A1 (en) 2018-01-18
CO2017013293A2 (es) 2018-05-31
EP3607939A1 (en) 2020-02-12
EA201792592A1 (ru) 2018-06-29
EP4233846A3 (en) 2023-10-04
CL2017003320A1 (es) 2018-07-13
PL4070787T3 (pl) 2023-07-24
CU20170168A7 (es) 2018-07-05
KR102313668B1 (ko) 2021-10-19
KR20180021134A (ko) 2018-02-28
EP3316868B1 (en) 2020-02-19
US20250281412A1 (en) 2025-09-11
EP3607939B1 (en) 2022-06-01
IL256364A (en) 2018-02-28
PL3316868T3 (pl) 2020-10-19
EP4233846B1 (en) 2024-12-04
ES2925246T3 (es) 2022-10-14
ES2945896T3 (es) 2023-07-10
PH12017502431A1 (en) 2018-07-02
CA2990210C (en) 2021-01-12

Similar Documents

Publication Publication Date Title
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
EA201792591A1 (ru) Фармацевтические препараты
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
MX388699B (es) Formas cristalinas de cabotegravir de sodio
TR201721700A2 (tr) Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari
CL2017000026A1 (es) Formas de dosificación farmacéutica
AR100153A1 (es) Medicamento
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
CO2020006701A2 (es) Composiciones farmacéuticas orales de lorazepam resistentes al alcohol
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
AR099971A1 (es) Forma de dosificación unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolítico que comprende darunavir y ritonavir
UA109243U (uk) Тверда лікарська форма, що містить інгібітор віл протеази
TR201722102A2 (tr) Levodropropizin İçeren Farmasötik Bir Ürün
EA201790387A1 (ru) Фармацевтическая композиция для лечения острой зубной боли или боли в челюсти
TR201619983A2 (tr) Di̇klofenak ve eletri̇ptanin farmasöti̇k formülasyonlari
UA114828C2 (uk) Застосування декаметоксину як фармацевтично активної речовини для лікування шлунково-кишкових та кишкових інфекцій перорально